EXHIBIT JG-2

JEFFREY N. GIBBS

700 Thirteenth Street, N.W., Suite 1200
Washington, D.C. 20005 (202) 737-5600

EXPERIENCE

Jan. 1991 to present	Director, Hyman, Phelps & McNamara, P.C., Washington, D.C.
1986 to 1990	Partner, Mackler and Gibbs, P.C., Washington, D.C.
1984 to 1986	Associate, Hogan & Hartson, Washington, D.C.
1980 to 1984	Associate Chief Counsel for Enforcement, United States Food and Drug Administration, Rockville, Maryland.
Sep. 1982 to Apr. 1983	Special Assistant United States Attorney, District of Columbia.
1978 to 1980	Law Clerk, Honorable Frederick B. Lacey, United States District Court for the District of New Jersey.

EDUCATION

1975-1978	New York University School of Law, New York, New York.
	Awarded Juris Doctor; graduated cum laude. Order of the Coif. Projects Editor of Law Review.
1971-1975	Princeton University, Princeton, New Jersey
	Awarded Bachelor of Arts; graduated summa cum laude.

MEMBERSHIPS

Bar: Member of the Bars of the State of New Jersey and the District of Columbia; the United States District Courts of New Jersey and the District of Columbia.

Other: Member, George Mason University Human Subjects Research Board (2003-present); Member, Food and Drug Law Journal Editorial Advisory Board (1998-2004); Member of Human Subject Research Board, George Mason University; Member of Editorial Advisory Board of In Vitro Diagnostic Technology; Member of Editorial Advisory Board of Guide to Good Clinical Practices; Chair of Food and Drug Law Journal Editorial Advisory Board (2003-04); Board of Trustees, Associates of Clinical Pharmacology (1993-95); United States Department of Agriculture Biotechnology Research Advisory Committee (1988-90).

AUTHORED PUBLICATIONS

Books:

Co-author: Biotechnology and the Environment: International Regulation (Macmillan 1987).

Articles:

"Exploring Other Options, Part 1: The trend toward alternative market pathways," IVD Technology, Volume 11, Number 4, May 2005.

"FDA Must Reform its Arbitrary Drug Name Review Process," Washington Legal Foundation, Vol. 20 No. 5, January 2005.

"Is Veterinary Compounding Illegal Under Federal Law?" International Journal of Pharmaceutical Compounding, Vol. 8 No. 6, November/December 2004.

"State Regulation of Pharmaceutical Clinical Trials," Food and Drug Law Journal, Vol. 59 No. 2 (2004).

"The Past, Present, and Future of ASRs," IVD Technology, November/December 2003.

"Compounding and the Courts," International Journal of Pharmaceutical Compounding, July/August 2002.

"Compliance Auditing," MX Magazine, Business Strategies for Medical Technology Executives, May/June 2002.

"FDA tightens the reigns, for better or for worse," Biotechnology, Investors' Forum, Worldwide Issue 1-2002.

"Informed Consent for IVD Studies: The Manufacturer's Role," IVD Technology, November/December 2001.

"Clinical Trials: What Executives Need to Know," MX Magazine, Business Strategies for Medical Technology Executives, January/February 2001.

FDA's Restitution "Authority" Relies Upon Flawed Court Ruling, Legal Opinion Letter, October 6, 2000.

Regulations and Standards. IVDs and the states: The other regulatory system, IVD Technology, September 2000.

Regulatory Due Diligence: An Ounce of Prevention, Medical Device Executive Portfolio, June/July 2000.

Human tissue acquisition: New regulatory and ethical issues, IVD Technology, Vol. 6 No. 2, March/April 2000.

Device Companies and Contracts: Don't Overlook the Regulatory Implications, Medical Device & Diagnostic Industry, August 1999.

Regulatory options for IVDs: Selecting the best path to market, IVD Technology, Vol. 5 No. 2, March/April 1999.

First Amendment Limits on Regulating Information: An Initial Reaction to the *Washington Legal Foundation* Case, Food and Drug Law Journal, Vol. 53 No. 4 (1998).

Regulations and Standards: Free-speech decision could advance off-label IVD promotion, IVD Technology, Vol. 4 No. 7, November/December 1998.

Regulations and Standards: FDA makes a better rule for IHCs, IVD Technology, Vol. 4 No. 5, September 1998.

FDA's New Financial Disclosure Rule: An Unnecessary New Burden, Medical Device & Diagnostic Industry, August 1998.

Final Rule on Financial Disclosure May Have a Significant Impact, Regulatory Affairs Focus, Vol. 3 Issue 6, June 1998.

FDA's RUO/IUO Policy: A Small Step Forward, IVD Technology NEWS, Vol. 4 No. 2, March/April 1998.

Industry-Supported Educational Programs: FDA's Final Policy, Regulatory Affairs Focus, Vol. 3 Issue 3, March 1998.

ASRs: FDA Issues Final Rule, IVD Technology, Vol. 4 No. 1, January/February 1998.

Avoiding the Liability Pitfalls of Internal Electronic Mail, Regulatory Affairs Focus, Vol. 2 Issue 8, August 1997 (co-authored with Alan M. Kirschenbaum).

When to Submit a New 510(k): FDA's Newest Guidance, Regulatory Affairs Focus, Vol. 2 Issue 5, May 1997.

Treatment IDEs: FDA Proposal Borrows from Treatment INDs, Regulatory Affairs Focus, Vol. 2 Issue 4, April 1997.

Banked Human Tissue: A Case Study in Agency Regulation, Regulatory Affairs Focus, Vol. 1, Issue 6, June 1996.

The Human Genome, FDA and Product Liability, RISK, Vol. 7 Issue 3, Summer 1996.

Legislation & Congressional Hearings Affecting The Outcome of FDA & Medical Manufacturers Reviewed, Biomedical Market Newsletter, October 1995.

FDA and Civil Money Penalties: New Regulations Change the Playing Field, RAPS News, October 1995.

FDA Enforcement: Its Impact on Civil Liability, RAPS News, September 1995.

FDA Certification: Signer Beware, RAPS News, June 1995.

FDA Inspections of Pharmacies: What Should You Do?, American Pharmacy, May 1995.

The WLF Case: A Challenge to FDA Regulation by Policy, RAPS News, May 1995.

FDA Financial Disclosure Proposal Should be Withdrawn, Legal Backgrounder, April 1995.

Commentary, IRB Approval for IVD Clinical Trials: An Unnecessary Burden, Medical Device & Diagnostic Industry, April 1995.

States and Health Care Manufacturers: Another Layer of Regulation?, RAPS News, April 1995.

The Device Approval Process, Industry Survey Results are Mixed, RAPS News, March 1995.

FDA' s Financial Disclosure Proposal a Bad Idea, Applied Clinical Trials, Volume 4, Number 1, January 1995.

FDA Proposes New Drug and Biologic Reporting Requirements, RAPS News, January 1995.

A Quartet of Updates, RAPS News, December 1994.

FDA Proposes New Financial Disclosure Rule, RAPS News, November 1994.

Deferred Consent: A Viable Option for Investigations of Emergency Use Therapies?, RAPS News, October 1994.

The Equal Access to Justice Act and the FDA, RAPS News, August 1994.

The Anatomy of a Consent Decree, RAPS News, July 1994.

The Prescription Drug Marketing Act Proposed Regulation: A Preamble for Everybody, RAPS News, June 1994.

Adverse Event Reporting: Confidential Information?, RAPS News (May 1994).

The FDA Expands Its Regulation of Product Marketing, Product Management Today (April 1994).

Contracting for Informed Consent?, RAPS News (March 1994).

FDA Regulation of Promotional Activities: An Update, RAPS News (February 1994).

Survey Finds Low Scores for FDA's Device Approval Process, RAPS News (January 1994).

FDA Update, RAPS News, (December 1993).

Civil Penalties: FDA's Newest Enforcement Tool, RAPS News, (November 1993).

Informed Consent and Clinical Trials, RAPS News (October 1993).

Monitoring Clinical Trials: Liability Issues, RAPS News (September 1993).

The New Honor System: Increased Auditing? RAPS News (August 1993).

GMP Regulations: New Guidelines From The Courts, RAPS News (July 1993).

CDRH's Product Review Process and the "Committee for Clinical Review," RAPS News (June 1993).

Product Liability: Is Some Judicial Relief At Hand?, RAPS News (April 1993).

FDA Should Stay Bound By Its Advisory Opinions, 3 Legal Opinion Letter 6 (March 1993).

Regulatory Predictability and Certainty: A Backwards Step?, RAPS News (March 1993).

FDA's New Draft Policy On Industry-Supported Scientific And Educational Activities, RAPS News (February 1993).

Survey Shows Growing Trend Away From U.S. For Device Companies, The Food and Drug Law Institute Update, No. 4 (1992).

FDA Steps Up Regulation Of Advertising And Promotion, RAPS News (December 1992).

FDA Regulation and Product Liability Litigation: A Hobson's Choice, RAPS News (October 1992).

Medical Devices and FDA Enforcement, RAPS News (September 1992).

It's The Law, Medical Device Update, RAPS News (August 1992).

Medical Device Promotional Activities and Private Litigation, 47 Food and Drug Law Journal, 3 (1992).

Institutional Review Boards and Informed Consent, 8 Food, Drug, Cosmetic and Medical Device Law Digest, 3 (September 1991).

Clinical Investigations and the FDA, 23 SRA News, (June 1991).

Reporting to the FDA: New Requirements and New Concerns, 23 SRA News 1 (March/April 1991).

New Medical Device Law Expands FDA Authority, 23 SRA News 1 (January/February 1991).

Clinical Investigations of Medical Devices: Investigational Device Exemptions, 8 Food, Drug, Cosmetic and Medical Device Law Digest 5 (Jan. 1991).

New Medical Device Legislation Enacted, 2 Regulatory Affairs 505 (Winter 1990).

Clinical Investigations: Six Common Mistakes and How to Avoid Them, 2 Regulatory Affairs 377 (Winter 1990).

Device Competitors: Playing on a Level Field, 12 Medical Device & Diagnostics Industry, 105 (June 1990).

Bioengineered Health Care Products and the FDA, National Health Lawyers Assn. Monograph (1990).

Biopharmaceuticals, FDA, and the Environment: Look Before You NEPA, BioPharm (July-Aug. 1989).

The Eden Foods Case: Lessons for the Industry, 3 Soya Newsletter 4 (1989).

Medical Devices and Regulatory Letters: An Analysis of FDA Enforcement Actions, 8 Medical Device & Diagnostics Industry 42 (Aug 1987).

Lasers and Product Liability, 5 Laser Medicine & Surgery News 4 (June 1987).

Exporting Biotechnology Products: A Look at the Issues, 5 Bio/Technology 46 (Jan 1987).

Federal Regulation of Bioengineered Veterinary Drugs, 4 Bio/Technology 414 (May 1986).

Co-author:

Just Sign on the Dotted Line?, Legal Times, Vol. XXVIII, No. 25, Week of June 20, 2005 (co-authored with Anne Marie Murphy).

The Wedgewood Cases: What it Means for Pharmacies, International Journal of Pharmaceutical Compounding, Volume 8, No. 1, January/February 2004 (co-authored with Jeffrey N. Wasserstein).

Ripe for Revision: Reassessing the Constitutionality of Food and Drug Administration Restrictions on Protected Speech, Food and Drug Law Journal, Volume 58, Number 3, 2003 (co-authored with Paul L. Ferrari and Anne Marie Murphy).

Can FDA Seek Restitution or Disgorgement, Food and Drug Law Journal, Volume 58, Number 2, 2003 (co-authored with John R. Fleder).

Western States Medical Center: A Watershed Moment for FDA's Regulation of Commercial Speech, Food and Drug Law Institute - Update, Issue 1, January/February 2003 (co-authored with Jeffrey N. Wasserstein).

Understanding FDA's Electronic Records and Signatures Regulation, Medical Device & Diagnostic Industry, May 1999 (co-authored with Kate Duffy Mazan).

Top 10 Changes in Regulatory Affairs, Regulatory Affairs Focus, Vol. 1, Issue 9, September 1996 (co-authored with Paul M. Hyman).

Warning Letters, One of FDA's Enforcement Tools, The Monitor, Vol.9 Issue 9, Fall 1996 (co-authored with Gail P. Middlekauff).

Deferred Consent: A Viable Alternative to Informed Consent?, Guide to Good Clinical Practice, Special Report, (co-authored with Alan G. Minsk), August 1994.

Food and Drug Administration Regulation and Products Liability: Strong Sword, Weak Shield, 22 Tort & Insurance Law Journal 194 (Winter 1987).

The Impact of Veterinary Drug Cases on Drug Approvals: An Update, in The Complete Handbook of Approved New Animal Drug Applications in the United States (1987).

Federal Regulation of Food and Food Additive Biotechnology, 38 Administrative Law Review 1 (Winter 1986).

Biotechnology and the Food Industry: Leaping the Regulatory Hurdles, 4 Bio/Technology 199 (March 1986).

Reusing Disposable Medical Devices: Legal and Economic Consequences, Engineering in Medicine and Biology 32 (June 1985).

The Food and Drug Administration and Its Impact on Medical Malpractice Cases, Proceedings of the Seventh World Congress on Medical Law (1985).

Reuse of Disposable Medical Devices: Regulatory and Liability Issues, 2 HealthSpan 12 (July 1985).

The Impact on Medical Malpractice Cases of Food and Drug Administration Regulation, 20 The Forum 418 (1985).

Contributing author:

New Developments in Biotechnology: Ownership of Human Tissues and Cells (Office of Technology Assessment, 1987).

The Role of FDA Device Regulation in Medical Malpractice Litigation, 7 Medical Device and Diagnostic Industry 40 (July 1985).

Premarket Approval versus Premarket Notification: Different Routes to the Same Market, 39 Food Drug Cosmetic Law J. 510 (1984).

Adulteration and Misbranding of Drugs: Fundamentals of Law and Regulations, Vol. II, An in-depth look at therapeutic products, (FDLI 1997).